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Abbreviations 
 
ADAM ADAM metallopeptidase 
AK  adenylate kinase 
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4EBP-1       eukaryotic translation initiation factor 4E binding protein 
1 
EPHA2            EPH receptor A2 
ERBB4  v-erb-a erythroblastic leukemia viral oncogene homolog 
4 
ERK  extracellular signal–regulated kinase 
FAK  focal adhesion kinase 
FISH  fluorescent in situ hybridization 
HGF  hepatocyte growth factor 
HIF-1α  hypoxia-inducible factor-1α 
HRAS              v-Ha-ras Harvey rat sarcoma viral oncogene homolog 
GF growth factors 
GNAQ guanine nucleotide binding protein (G protein), q 
polypeptide 
GRIN2A glutamate receptor, ionotropic, N-methyl D-aspartate 
2A 
IC50 growth-adjusted inhibitory concentration of 50% 
IGF1R insulin-like growth factor 1 receptor 
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog 
MALDI-TOF matrix-assisted laser desorption/ionization time-of-flight 
MAPK mitogen-activated protein kinase 
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MC1R melanocortin-1 receptor 
MEK MAPK/ERK kinases 
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pTyr phosphorylated tyrosine  
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S6K S6 kinase 
SHC Src homology 2 domain–containing transforming 
protein 
siRNA             small interfering RNA 
SRC v-src sarcoma viral oncogene homolog 
STAT3 signal transducer and activator of transcription 3 
TGFβ      transforming growth factor, beta 
TP53 tumor protein p53 
VEGF vascular endothelial growth factor 
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Abstract 
 
The clinical activity of the BRAF inhibitor PLX4032 (vemurafenib) in 
patients with BRAFV600E mutant melanoma is limited primarily by the 
development of resistance leading to tumor progression. Strategies to 
overcome primary and acquired resistance are required. In a panel of 27 
genetically characterized patient-derived melanoma cell lines the 
sensitivity to PLX4032 was dependent on BRAFV600E and independent 
from other gene alterations that commonly occur in melanoma, such as 
CDKN2A, and mutations of TP53, PTEN loss, and BRAF and MITF gene 
amplification. To investigate the molecular basis underlying acquired 
resistance to BRAF inhibitor, PLX4032-resistant cells were derived from 
a high sensitive BRAFV600E melanoma cell line, and used as a model. 
The resistant variant line showed increased AKT and ERK 
phosphorylation and enhanced IGF-1R/PI3K signaling. Combined 
treatment with PLX4032 plus PI3K inhibitors resulted in significant cell 
growth inhibition by decreasing pAKT and pERK signaling. To explore 
molecular mechanisms underlying primary resistance two melanoma cell 
lines lacking sensitivity to PLX4032 were used as models. Resistance to 
PLX4032 was maintained after CRAF down-regulation by siRNA, 
indicating that CRAF is not involved in the activation of ERK in the 
resistant cell lines. Treatment with the MEK inhibitor UO126 inhibited cell 
growth and decreased ERK phosphorylation indicating alternative 
activation of MEK-ERK signaling. Genetic characterization by MLPA and 
analysis of pTyr signaling by MALDI-TOF mass spectrometry revealed 
the activation of MET and SRC signaling, associated with the 
amplification of MET and of CTNNB1 and CCND1 genes, respectively. 
Testing of co-inhibition of the MET, SRC and MAPK signaling pathways 
by the combined treatment with the MET inhibitor, SU11274 or the SRC 
inhibitor, BMS-354825 plus PLX4032 resulted in a significant inhibitory 
effect on melanoma cell proliferation, survival, migration and invasive 
capacity. 
These results support combinatorial approaches targeting MAPK 
pathway at different nodes and intercepting parallel signal transduction 
pathways as a strategy to override resistance to BRAF inhibitors.  
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State of the Art 
 
Melanoma is an aggressive form of skin cancer and its incidence is on 
the rise worldwide. It is highly invasive and resistant to conventional 
therapy, making it the most lethal of human skin cancers. If melanoma is 
diagnosed early it can be cured by surgical resection, and about 80% of 
cases are dealt with in this way. Metastatic malignant melanoma is 
refractory to current therapies and has a very poor prognosis. The 
median survival rate for patients with metastatic disease is 8-9 months 
(Balch et al, 2009). Only recently, clinical trials of chemotherapy and of 
immunotherapy have shown significantly improved survival. Recent 
discoveries in the complex networks involved in melanoma proliferation, 
potential progression and survival have created many opportunities for 
targeted drugs and therapeutic approaches for this disease.  
 
1. Melanoma subtypes  
 
Cutaneous melanoma arises from the transformation of skin 
melanocytes, the melanin-producing cells located in the basal layer of 
the epidermis. By distributing pigment from melanosomes to 
keratinocytes melanocytes exert a protective role for the skin against UV 
radiation. Over 90% melanomas originate as cutaneous lesions, while 
5% develop in mucosal surfaces (oral, gastrointestinal, ano-rectal, and 
vaginal) (Papaspyrou et al, 2011) and 5% in the uveal tract of the eye 
(Harbour et al, 2012). Cutaneous melanomas are classified into four 
major clinical-histologic subtypes (Clark et al, 1969; McGovern et al, 
1973): 1- superficial spreading melanoma mostly occurring on areas of 
the body with intermittent sun exposure, such as the trunk and proximal 
extremities; 2- lentigo maligna melanoma associated with chronic sun-
exposed areas of the body, such as the head; 3- acral melanoma mostly 
occurring on non sun-exposed regions, such as the palms, nail beds and 
soles of the head. This classification is however not predictive of disease 
progression, outcome and treatment response. The current melanoma 
staging system developed by American Joint Committee on Cancer 
staging system is based on primary tumor thickness, presence or 
absence of ulceration and of mitoses as well as on the extent of spread 
in regional lymph nodes and at distant body (Balch et al, 2009).  
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2. Mutations affecting key biological pathways in melanoma 
 
Figure 1. Summary of key pathways and genes frequently mutated in melanoma 
(modified from Dutton-Regester and Hayward, 2012). 
 
Melanoma possesses a complex biological behavior resulting from a 
diverse range of genetic mutations. Somatic mutations are acquired 
during an individual’s lifespan through environmental factors, primarily 
UV light exposure (Polsky and Cordon-Cardo, 2003). Genomic data 
support that UV light is the primary arbiter of high mutation rate observed 
in melanoma sequencing studies, as it induces point mutations causing 
nucleotide substitutions of thymine with cytosine (C>T) (Pleasance et al, 
2010; Wei et al, 2011). Many somatic mutations have been identified in 
melanoma, not surprisingly a number of these occur in genes within the 
same biological pathways. The genes affected by mutations include 
oncogenes and tumor suppressor genes, namely CDKN2A, TP53, PTEN 
tumor suppressors and BRAF, NRAS, CKIT oncogenes which are 
defined ‘classical melanoma genes’. (Dutton-Regester and Hayward, 
2012). The advent of high-throughput technologies for sequencing have 
lead to significant progress in discovering and compiling mutation events 
in melanoma, adding a novel layer of complexity of analysis in discerning 
‘driver’ mutation events responsible for the development of the tumor to 
those that are ‘passenger’ events (Walia et al, 2012). This is of particular 
significance in understanding the etiology of melanoma, with the 
observation of significantly higher rates of mutations in melanoma 
compared to other tumor types (Pleasance et al, 2010; Wei et al, 2011; 
Walia et al, 2012).  A number of biological pathways and potential 
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Rb
targets to therapeutic intervention have been identified in these studies 
including ERBB4, matrix metalloproteinases (MMP) and GRIN2A genes, 
as shown in Figure 1. Somatic ERBB4 gene mutations resulting in 
hyperactivation of the ERBB4 receptor (Kurppa et al, 2009) have been 
identified in 19% of malignant melanoma (Prickett et al, 2009). The MMP 
have recently been shown to be frequently mutated in melanoma 
(Palavalli et al, 2009). A mutational analysis of 19 metalloproteinases-
ADAM genes in human cutaneous metastatic melanoma identified eight 
to be somatically mutated, affecting 34% of the melanoma tumors 
analyzed (Wei et al, 2011).  Functional analysis of the two frequently 
mutated ADAM genes, ADAM29 and ADAM7 demonstrated that the 
mutations affect adhesion of melanoma cells to specific extracellular 
matrix proteins and in some cases increase their migration ability, 
suggesting a role in melanoma progression. GRIN2A is mutated in 33% 
of melanoma samples (Wei et al, 2011). The mechanism by which 
mutations in GRIN2A have a tumorigenic effect is unclear; however, their 
frequency strongly suggests that they play a major role in melanoma and 
are worthy of future investigation. 
 
3. Key signaling pathways implicated in melanoma  
 
The implementation of novel high-throughput biotechnologies has led to 
the identification of a number of molecular pathways and genes involved 
in melanoma pathogenesis and progression. Melanoma develops 
through the disruption of the complex interconnected signaling pathways 
controlling cell proliferation, senescence and apoptosis. The most 
frequently altered biological pathways involved in melanoma progression 
are the RAS/RAF/MEK/ERK and PI3K/AKT pathways. 
 
 
 
 
 
 
 
Figure 2. Signaling pathways 
implicated in melanoma 
(Modified from Vidwans et al, 
2011). 
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3.1 RAS/RAF/MEK/ERK pathway 
 
One of the most well known and characterized pathways commonly 
abrogated in melanoma is the mitogen activating protein kinase (MAPK) 
signaling cascade. The MAPK pathway is a phosphorylation-driven 
signal transduction cascade that couples intracellular responses to the 
binding of growth factors (GF) to cell surface receptors (Figure 2). In 
response to a variety of cellular stimuli, the G-protein RAS assume an 
activated state, leading to recruitment of RAF family (ARAF, BRAF and 
CRAF) from the cytosol to the cell membrane where they become 
activated. Activated RAF causes the phosphorylation and activation of 
MAP kinase extracellular signal regulated kinases 1 and 2 
(MEK1/MEK2), which in turn phosphorylate and activate extracellular 
signal-regulated kinases 1 and 2 (ERK1/ERK2). Activated ERK 
translocate to the nucleus and phosphorylate several nuclear 
transcription factors (Elk-1, Myc, CREB, Fos and others) which bind 
promoters of many genes, including growth factor and cytokine genes 
that are important for stimulating cellular proliferation and survival, 
angiogenesis, invasiveness and metastasis. The MAPK pathway plays 
an important role in melanoma cell proliferation and survival, with ERK 
being constitutively activated in 90% of melanomas (Cohen et al, 2002). 
ERK hyperphosphorylation is due to mutations of NRAS (mutated in 10-
20% of melanoma), and expecially of BRAF genes (approximately 50%), 
and less frequently of MAP2K1, MAP2K2 (approximately 8%) (Dutton-
Regester and Hayward, 2012). Interestingly, NRAS and BRAF mutations 
are generally mutually exclusive events in melanoma, indicating that 
mutant BRAF or NRAS alone is able to activate the MEK/ERK pathway 
(Daniotti et al, 2004; Goel et al, 2006). Melanomas arising on non-
chronically sun damaged skin are associated with frequent activating 
mutations in BRAF, a relatively high in frequency of NRAS mutations 
and no KIT mutations. Conversely, melanomas arising from mucosae, 
acral surfaces and skin with chronically sun damage show infrequent 
mutations in BRAF and NRAS and KIT gene amplification or mutations 
(Curtin et al, 2005; Curtin et al, 2006). KIT, located on chromosome 
4q12, encodes a tyrosine kinase receptor for stem cell factor. Activation 
of KIT by ligand binding results in the stimulation of other signaling 
pathways producing proliferative and survival effects (Figure  2). 
Mutations result in constitutive activation of the KIT tyrosine kinase and 
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activation of multiple pro-survival signaling pathways including the MAPK 
and PI3K/AKT pathways. Genetic screens have shown that 46% of uveal 
melanomas exhibit mutations in GNAQ while are absent in cutaneous 
and mucosal melanomas (Onken et al, 2008; Van Raamsdonk et al, 
2009). GNAQ gene, located on chromosome 9q21, encodes the q class 
of G-proteins α-subunits, involved in transmitting signals between G 
protein-coupled receptors and their downstream pathways, including 
activation of protein kinase C family members which are able to activate 
the MAPK pathway (Figure 2). 
The microphtalmia-associated transcription factor (MITF), located on 
chromosome 3p14.1-p14.2, acts as a master regulator of melanocyte 
development, function and survival activated by MAPK signaling (Levy 
2006). In melanocytes differentiation, it functions downstream of several 
pathways, including MC1R, MET and KIT (Figure 2). MAPK 
phosphorylates MITF leading to transcription of MITF-dependent genes, 
many of which are involved in pigmentation and survival, such as the 
antiapoptotic gene Bcl-2.  
 
3.2 PI3K/AKT/mTOR pathway 
 
The posphatidylinositol-3-kinase (PI3K) pathway is commonly altered in 
melanoma because of mutations in PTEN or activation of AKT resulting 
from tyrosine kinase receptors (RTK) activation (Figure 2).  
The tumor suppressor gene PTEN, located on chromosome 10q23.3, 
encodes the lipid phosphatase PTEN, a negative regulator of PI3K/AKT 
pathway by dephosphorylating phosphatidylinositol-3,4,5-triphosphate 
(PIP3) in phosphatidylinositol-4,5-biphosphate (PIP2) (Robertson et al, 
2005). Deletions or mutations in PTEN are found in about 40% of 
melanomas (Rodolfo et al, 2004), but low expression level of PTEN may 
be seen in 50% of melanomas, probably as a result of epigenetic 
silencing, altered subcellular localization, or ubiquitination (Zhou et al, 
2000). In response of GF receptors the PI3K phosphorylates PIP2 to 
PIP3, leading to activation of the major downstream effector of the PI3K 
pathway, AKT/protein kinase B. Once activated, AKT phosphorylates its 
substrates including the serine/threonine kinase mammalian target of 
rapamycin (mTOR) which then phosphorylates S6 kinase (S6K) and 
inhibits 4E-BP, leading to increased protein translation as well as other 
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targets that regulate cell division and translation. mTOR is found to be 
activated in 73% human melanoma cell lines (Karbowniczek et al, 2008).  
AKT/protein kinase B is a serine protein kinase constitutively activated in 
about 60% of melanomas (Stahl et al, 2004). Recent studies have 
revealed deregulation of the PI3K signaling in a high proportion of 
melanomas. The three isoforms of AKT, namely, AKT1, AKT2 and 
AKT3, have different effects on cell proliferation. AKT3 is preferentially 
activated in melanoma in 43-60% of melanomas (Stahl et al, 2004). 
Mutations in PIK3CA locus, the gene encoding the catalytic subunit of 
PI3K, do not contribute to mechanisms of AKT deregulation, because 
are detected at very low frequencies (<5%) in melanoma (Omholt et al, 
2006). Increased phospho-AKT (pAKT) expression in melanoma is 
associated with tumor progression and shorter survival (Fecher et al, 
2007). Oncogenic RAS can also bind and activate PI3K, resulting in 
increased AKT activity (Sekulic et al, 2008). Inhibition of PI3K signaling 
can diminish cell proliferation and promote cell death. Consequently, 
inhibitors against multiple components of the PI3K/AKT pathway such as 
LY294002 and wortmannin, have been developed and are in various 
stages of clinical testing (Courtney et al, 2010).  
 
4. BRAF as a therapeutic target 
 
The BRAF gene, located on chromosome 7q34, encodes for a serine-
threonine protein kinase and is the most commonly mutated gene in 
melanoma, observed in 50% of melanoma (Davies et al, 2002). 
Ninetyfive % mutations of BRAF occur in exon 15, which encodes the 
catalytic domain of the BRAF protein, and determine the substitution at 
the valine with glutamic acid at  position 600 (V600E). Alternative point 
mutations at the same position (V600K, V600D, V600R) contribute for 5-
6% of the total (Long et al, 2010). The V600E mutation introduces a 
conformational change in the kinase domain that increase the activity of 
the kinase resulting in >10-fold more active than the wild-type kinase. 
BRAFV600E mutation leads to constitutive activation and 
phosphorylation of MEK/ERK pathway by phosphorylating MEK, 
stimulating cancer cell proliferation and survival (Davies et al, 2002).  
Mutant BRAF transmits survival signals through a variety of cytoplasmic 
and cytoskeletal targets and initiates nuclear transcription, resulting in 
expression of several cancer-associated genes, including those for 
BRAF as a target for malignant melanoma  
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cyclin D, hypoxia-inducible factor-1α (HIF-1α), vascular endothelial 
growth factor (VEGF), MMP, urokinase and integrins regulating cellular 
proliferation, angiogenesis, tissue invasion and metastases (Kohno et al, 
2006; Kumar  et al, 2007; DeLuca et al, 2008). 
BRAFV600E mutation is an early mutational event since it is detected 
also in nevi suggesting that BRAFV600E alone is not sufficient for 
malignant transformation and additional alterations are needed for 
melanocyte transformation (Pollock et al, 2003; Kumar et al, 2004). The 
association of BRAF mutation with PTEN (Dankort et al, 2009), p16 
(Dhomen et al, 2009), p53 (Patton et al, 2005) genes has been 
described. It has been reported that melanocortin-1 receptor (MC1R) 
variants increase the risk of melanoma with BRAF mutations leading to 
the hypothesis that BRAF activation may be indirectly induced by UV 
radiation (Landi et al, 2006; Fargnoli et al, 2008; Scherer et al, 2010).  
The frequency and specificity of BRAFV600E mutation, together with the 
strict dependence of melanoma cell growth and survival on BRAFV600E 
activity, a phenomenon called oncogene addiction, have pointed to 
BRAFV600E as a promising therapeutic target. BRAF depletion by 
siRNA inhibited the MAPK cascade, induced growth arrest, and 
promoted apoptosis (Hingorani et al, 2003; Karasarides et al, 2004). 
Several authors have reported a BRAF mutation-associated gene 
expression signature in melanoma cells by microarray analysis (Pavey et 
al, 2004; Bloethner et al, 2005; Johansson et al, 2007). In particular, 
genes that encode proteins involved in RAS/RAF/MEK/ERK signaling 
were identified among the genes differentially expressed between 
melanoma cell lines with or without BRAF mutation (Bloethner et al, 
2005) that potentially represent novel therapeutic targets.  
 
A series of small molecules which inhibit BRAF activity have been 
developed. The first BRAF inhibitor to be investigated in melanoma was 
the multikinase inhibitor sorafenib (BAY43-9006), which targets BRAF as 
well as CRAF, platelet-derived growth factor receptor β (PDGFRβ), and 
vascular endothelial growth factor receptor (VEGFR) (Wilhelm et al., 
2004). Sorafenib was tested in melanoma patients as monotherapy and 
combined with cytotoxic chemotherapy-dacarbazine (McDermott et al, 
2008), temozolomide (Amaravadi et al, 2009), and carboplatin plus 
paclitaxel (Hauschild et al, 2009) with negative results. Then, a new 
generation of highly specific and potent BRAF inhibitors has been 
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developed. Two agents have recently demonstrated significant clinical 
benefit in melanoma, vemurafenib and dabrafenib. Vemurafenib 
(PLX4032/RG7204/RO5185426, zelboraf) is an highly specific ATP 
competitive inhibitor of BRAFV600E. PLX4032 is also effective against 
V600K mutation (Rubinstein et al, 2010). PLX4032 suppresses the 
activated oncogenic pathway by inhibiting the ERK kinase cascade, as 
evidenced by the inhibition of phosphorylated ERK (pERK). Phase I/II 
trial resulted in an 80% response rate, as determined by complete or 
partial tumor regression, in patients with BRAFV600E tumors whereas 
patients without the mutation did not respond (Flaherty et al, 2010; 
Chapman et al, 2011; Sosman et al, 2012). This is the highest response 
rate to date for a melanoma drug. However, the responses are 
temporaneous and resistance to BRAF inhibitors emerges within few 
months. Side effects include skin rash, photosensitivity, hair loss, 
fatigue, joint pain and skin tumors, mostly squamous-cell carcinomas 
and keratoacanthomas, in 15-30% of patients (Robert et al, 2011). 
Another specific inhibitor is dabrafenib (GSK2118436), an ATP 
competitive inhibitor of the mutant BRAF V600E/D/K. In a phase I/II 
study, 60% melanoma patients with mutant BRAF had more than 20% 
tumor reductions (Kefford et al, 2010); notably, reduction of brain 
metastases was observed (Long et al, 2010). GSK2118436 is under 
evaluation in a phase II study for the treatment of patients with brain 
metastases, and a phase I study has commenced of GSK2118436 in 
combination with the MEK inhibitor GSK1120212. Side-effects were very 
similar to what has been observed with PLX4032. Both PLX4032 and 
GSK2118436 were reported to have a stimulatory effect on MAPK 
pathway in cell lines with wild type BRAF that harbor upstream pathway 
activation such as oncogenic RAS or upregulated receptor tyrosine 
kinases (Poulikakos et al, 2010; Hatzivassiliou et al, 2010). This effect is 
probably driven by the formation of RAF dimers that lead to signaling 
through CRAF and consequent MAPK pathway hyperactivation (Heidorn 
et al, 2010). This phenomenon may explain the appearance of 
secondary skin tumors which are characterized by frequently mutations 
in HRAS (Su et al, 2012). 
MEK and ERK kinases lie downstream of BRAF in the signaling pathway 
and are other potential targets of new drugs. Several MEK inhibitors are 
under evaluation for the treatment of metastatic melanoma, such as 
AZD6244 and GSK1120212 which demonstrated an objective response 
BRAF as a target for malignant melanoma  
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rate of 44% with a median progression free-survival of 7 months (Infante 
et al, 2010).  
 
4.1. Resistance mechanisms to BRAF inhibition 
 
Resistance to BRAF inhibition includes primary resistance or insensitivity 
to treatment and secondary resistance, acquired after chronic treatment. 
Primary resistance defines those tumors that progress early in the 
course of therapy, whereas secondary resistance connotes progression 
after an initial response. Primary resistance to BRAF inhibition is 
observed in 20% of patients with BRAF mutant melanoma treated with 
PLX4032 (Flaherty et al, 2010). Preclinical studies have identified 
elevated levels of CRAF are associated to primary resistance to BRAF 
inhibition (Montagut et al, 2008) in addition to CCND1 gene 
amplification, overexpression of cyclin D1 and of CDK4 (Smalley et al, 
2008). The majority of patients responded to PLX4032 and GSK2118436 
treatment but relapsed within 2-18 months and developed resistance to 
the treatment (Flaherty et al, 2010; Arkenau et al, 2011).  
To date, preclinical studies have identified multiple mechanisms of 
acquired resistance to BRAF inhibitors, some of which were shown to 
occur in metastatic lesions from treated patients. Reactivation of the 
MAPK pathway seems to be involved in the majority of the cases of 
acquired resistance but signaling transduction by parallel pathways was 
also identified (Johannessen et al, 2010; Nazarian et al, 2010; Wagle et 
al, 2011). In general, acquired resistance mechanisms can be classified 
into ERK-Dependent and ERK-Independent mechanisms (Figure 3 and 
Table 1). 
 
 
 
 
 
 
 
Figure 3.  
Mechanisms of 
acquired resistance 
to BRAF inhibitors 
(Modified from Solit 
et al, 2010). 
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4.2.1 ERK-Dependent mechanisms 
 
The vast majority of acquired resistance mechanisms to BRAF inhibitors 
display reactivation of ERK signaling despite the presence of inhibitor. 
Elevated CRAF activity was identified as a mechanism of resistance to 
the BRAF inhibitor AZ628 in preclinical studies (Montagut et al, 2008). In 
AZ628 resistant clones generated in vitro from a BRAF mutant 
melanoma cell line, higher CRAF protein levels were detected, 
compared to drug sensitive parental cells, with tumor cells appearing to 
have switched signaling from BRAF to CRAF. However, no CRAF gene 
amplification was detected.  
While secondary mutations in the kinase domain of BRAF have not yet 
been identified as a cause of BRAF inhibitor resistance, Corcoran et al 
have identified amplification of the mutant BRAF allele in two 
independent BRAF mutant colorectal  cancer cell lines resistant to the 
MEK inhibitor AZD6244 (Corcoran et al, 2010).  
Furthermore, BRAF gene amplification was reported to occur in four out 
of twenty patients with acquired resistance to BRAF inhibitor PLX4032 
providing evidence for alterations in the drug target causing clinical 
relapse (Shi et al, 2012). 
The first resistance mechanism that involves a structural change in 
BRAF was reported by Poulikakos et al showing dimerization of 
aberrantly BRAFV600E splicing variants, lacking the RAS-binding 
domain, as a mechanism of acquired resistance to PLX4032 (Poulikakos 
et al, 2011). Acquired resistance mediated by BRAFV600E splicing 
variants is due to insensitivity of the enzyme to RAF inhibitors. The 
identification of BRAF variants in tumors from six of nineteen patients 
with acquired resistance to PLX4032, indicates the clinically importance 
of this mechanism. BRAF splicing variants were not detected in two 
samples derived from patients with intrinsic resistance, or in melanoma 
cell lines and tumor biopsies not exposed to BRAF treatment with 
inhibitors. 
NRAS mutations were identified as a mechanism of acquired resistance 
to the BRAF inhibitor PLX4032 (Nazarian et al, 2010). Cell lines resistant 
to PLX4032 were derived from three melanoma cell lines with 
BRAFV600E. In one of these cell lines an activating NRAS mutation 
(Q61K) was identified which was not detected in the original cell line. 
This mutation was also present in an isolated nodal metastasis from a 
BRAF as a target for malignant melanoma  
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patient with BRAF mutant melanoma, which progressed after an initial 
response to treatment with PLX4032. A second NRAS mutation, Q61R, 
was identified in a second progression site in the same patient. Mutated 
NRAS was known to induce a switch from BRAF to CRAF, resulting in 
persistent MAPK signaling (Dumaz et al, 2006). 
COT/MAP3K8, a MAPK downstream of BRAF, was identified as 
potential mediator of BRAF inhibitor resistance by employing cDNA 
expression for screening kinases able to confer resistance to PLX4720, 
a compound closely related to PLX4032 (Tsai et al, 2008; Johannessen 
et al, 2010). COT levels were observed to increase in cell lines treated 
with BRAF inhibitors, suggesting that it may be involved with feedback 
regulation of MEK activity. Moreover, COT expression was associated 
with intrinsic resistance in BRAFV600E cultured cell lines and sustained 
ERK phosphorylation in the presence of BRAF inhibitor. Biopsy samples 
from three patients with metastatic melanoma undergoing treatment with 
PLX4032 showed higher COT expression during treatment than before 
treatment, and high levels were detected in a relapse specimen. COT-
expressing cell lines were shown refractory not only to BRAF inhibition 
but also to MEK1/2 inhibitors. In the context of MEK inhibition, these cell 
lines showed sustained ERK phosphorylation, raising the possibility that 
COT may activate ERK through a MEK-independent mechanism as well 
as a MEK-dependent mechanism. ERK inhibition or direct COT inhibition 
may be needed to bypass this mechanism. 
Activating MEK1 point mutations (P124L, Q56P, C121S) were identified 
in resistant melanoma cells (Emery et al, 2009; Wagle et al, 2011). 
These mutations were characterized biochemically to activate ERK and 
could account for reactivation of MAPK signaling pathway. P124L MEK1 
mutation, was identified in a resistant metastatic focus that emerged in a 
melanoma patient treated with the MEK inhibitor, AZD6244. Both P124L 
and Q56P MEK1 mutants conferred cross-resistance to PLX4720, a 
selective B-RAF inhibitor (Emery et al, 2009). C121S MEK1 mutation 
was found in one tumor sample of a patient after disease progression on 
PLX4032 treatment, and in a second sample from a tumor excised 
before treatment (Wagle et al, 2011).  
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4.2.2 ERK-Independent mechanisms 
 
Several examples of resistance mechanisms have been reported that do 
not rely on sustained ERK signaling, indicating that ERK-independent 
pathways can maintain the tumorigenicity of BRAFV600E melanoma in 
the absence of ERK activation. The activation of signaling of RTK can 
bypass BRAF inhibition by activating parallel signaling pathways that 
redundantly regulate downstream mediators of cellular proliferation and 
survival, such as cyclin D1, BAD and 4E-BP1 (She et al, 2010). 
Activation of PDGFRβ was observed in three BRAF mutant melanoma 
cell lines made resistant to PLX4032 by chronic exposure compared to 
sensitive cell lines. Consistent with an ERK-independent resistance 
mechanism, the growth of PDGFRβ-overexpressing resistant cells was 
insensitive to MEK inhibitors. Four of eleven clinical post-relapse 
biopsies from melanoma patients treated with PLX4032 showed 
increased PDGFRβ expression compared to pre-treatment biopsies 
(Nazarian et al, 2010). RNAi-mediated knockdown of PDGFRβ led to 
growth inhibition in the presence of PLX4032, validating PDGFRβ as the 
cause of acquired resistance. However, the combination of PDGFRβ 
inhibitor and PLX4032 did not restore sensitivity to resistant cell lines 
indicating that additional mechanisms may contribute to resistance, 
possibly involving other RTK. 
The insulin-like growth factor 1 (IGF1R) signaling pathway was 
implicated in resistance to BRAF inhibitor SB-590885. IGF1R, as well as 
other RTK, is known to activate PI3K/AKT signaling. Resistant cells 
displayed elevated levels of phoshorylated IGF1R (pIGF1R) and AKT. 
Pharmacologic inhibition of IGF1R decreased proliferation and reduced 
pAKT levels in resistant cells. Combined inhibition of IGF1R and MEK 
induced apoptosis, suggesting that ERK-independent survival signaling 
was mediated by IGF1R in resistant cells (Villanueva et al, 2010). In 
addition, immunohistochemical analysis of five paired tissue sets from 
relapsed melanoma patients treated with PLX4032 showed increased 
expression of IGF1R in two patients, one of which also had increased 
levels of pAKT. In the post relapse sample of one patient without a 
concomitant IGF1R increase a homozygous loss of PTEN and increased 
levels of pAKT were found indicating that PTEN loss could be linked to 
resistance to BRAF inhibitors.  
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Mechanism 
Clinicalrelevance of in 
vitro acquired 
resistance studies 
Reference 
ER
K
-
 
D
ep
en
de
n
t 
BRAF amplification 
Not tested Corcoran et al, 2010 
4/20 patients Shi et al, 2012 
BRAF splicing variants 6/19 patients Poulikakos et al, 2011 
MEK1 mutation 1 patient Emery et al, 2009; Wagle et al, 2011 
NRAS mutation 2/16 biopsies from 1 patient Nazarian et al, 2010 
CRAF upregulation Not tested Montagut et al, 2008 
COT upregulation 3 patients Johannessen et al, 2010 
ER
K
-
 
In
de
pe
n
de
n
t 
PDGFRβ upregulation 4/11 patients Nazarian et al, 2010 
IGF1R upregulation 2/5 patients Villanueva et al, 2010 
 
      Table 1. Molecular mechanisms of acquired resistance to BRAF inhibitors 
Understanding the biology and deciphering the genetics of melanoma 
has been crucial for the development of new therapies. Due to the 
variety of the resistance mechanisms described so far, it appears that 
there is not a single strategy to bypass resistance to BRAF targeted 
drugs that will fit all patients. Compounds blocking multiple levels of the 
signaling pathways are being actively researched. The V600EBRAF 
inhibitor PLX4032 is now an approved agent for the treatment of 
advanced melanoma. However, this drug is suited only for 50% of the 
patients who carry metastatic melanoma with the BRAF mutation, and 
even in these patients the responses are transitory. For those not 
presenting the mutation, finding other targets is urgent. The combination 
of kinase inhibition with conventional cytotoxic chemotherapy, 
immunotherapy or multiple kinase inhibition guided by the tumor 
molecular profile are currently evaluated as new strategies for 
personalized melanoma treatment. 
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Aim of the Project 
 
Blocking oncogenic signaling induced by the BRAFV600E mutation is a 
promising approach for melanoma treatment. The specific BRAFV600E 
kinase inhibitor PLX4032 showed a remarkable clinical activity in 
patients with BRAF mutant melanoma. However, resistance to PLX4032 
develops after treatment and strategies to prevent and overcome 
resistance are required.  
To overcome PLX4032-resistance the following specific objectives were 
identified:  
 
- to evaluate PLX4032 activity on cell proliferation, apoptosis, cell 
cycle and downstream signaling pathways in a panel of 
BRAFV600E melanoma cell lines with defined genetic alterations 
 
- to characterize at the genetic and molecular levels melanoma cell 
lines showing poor sensitivity to PLX4032 
 
- to generate resistant cell line variants by chronic exposure to 
PLX4032 
  
- to identify and validate new potential targets for pharmacological 
intervention associated with the lack of sensitivity to PLX4032 by 
molecular studies 
 
- to evaluate the effects of the combination of PLX4032 with other 
kinase inhibitors to bypass resistance to BRAF inhibition. 
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Results and Discussion 
 
1. Effects of PLX4032 on growth and survival in BRAFV600E 
mutated melanoma cells 
 
The antiproliferative effects of PLX4032 was tested in 27 genetically 
characterized short term melanoma cell lines, including 20 lines 
heterozygous for the BRAFV600E mutation and 7 lines carrying wild 
type BRAF gene. Eighteen out of 20 BRAFV600E mutated melanoma 
cell lines were highly sensitive to growth inhibition by PLX4032 when 
evaluated by MTT proliferation assays, with IC50 in the µM range (0.01-
1), while two lines showed IC50 about 10 µM indicating primary 
resistance to the compound. The different IC50 values observed in the 
sensitive cell lines were not associated with alterations in CDKN2A, 
TP53, PTEN genes, amplification of BRAF or MITF genes, or to the 
expression of KIT protein. No effect on proliferation was detected in 
melanomas carrying wild type BRAF gene, indicating the specificity of 
PLX4032 for BRAFV600 mutated melanomas (Figure 1A).  
Studies in other cancer types suggest that activation of the PI3K 
pathway is one mechanism by which tumor cells may bypass apoptotic 
signals initiated through anti-tumor agents (Halilovic et al, 2010; Smalley 
and Sondak, 2010). PTEN loss in conjunction with BRAF mutation has 
been shown to enable melanoma cell proliferation and survival through 
activation of PI3K/AKT signaling pathway, possibly decreasing 
dependency of ERK signaling (Dankort et al, 2009). To evaluate the role 
of PTEN in the effects of PLX4032 it has been tested whether PLX4032 
exerted different effects in melanoma cell lines carrying or lacking intact 
PTEN. When response of melanoma cells to PLX4032 concentrations 
inhibiting cell growth was examined, an accumulation of cells in the G1 
phase in the majority of sensitive but not in resistant lines was found, 
indicating proliferative block. Independently of PTEN expression 
evaluation of apoptosis, detected by adenylate kinase (AK) release or by 
activated caspase-3 detection, showed higher levels of apoptotic cells in 
PTEN-positive samples, indicating a role for PTEN in the induction of cell 
death in response to PLX4032 (Figure 1B). Together, these data 
confirmed the high specificity of PLX4032 for BRAFV600E mutated cell 
lines independently of other common alterations occurring in melanoma. 
In addition, two cell lines carrying BRAFV600E mutation, LM20 and 
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LM38, and demonstrating resistance to the cytotoxic effects of PLX4032 
were identified.  
 
2. Modulation of MAPK and PI3K/AKT signaling pathways by 
PLX4032 in sensitive and resistant cell lines 
 
In an attempt to evaluate the signaling response associated to 
susceptibility to PLX4032, the effect of treatment on downstream 
pathways regulating cell growth and proliferation in BRAFV600E 
mutated melanomas was examined. Exposure to PLX4032 resulted in a 
marked decrease in pERK, pAKT and p-p70S6K, indicating that 
treatment with PLX4032 blocked the downstream signaling in most drug-
sensitive cell lines, independently of PTEN status (Figure 2). In addition, 
cyclinD1 expression was downregulated in all drug-sensitive cells, in 
agreement with a G1 accumation in the cell cycle. In contrast, treatment 
did not inhibit pERK, pAKT and p-p70S6K signaling in the resistant cell 
lines LM20 and LM38. These data suggest that these cell lines can 
survive in the absence of MAPK abrogation due to other oncogenic 
events beyond BRAF. 
 
3. Chronic BRAF inhibition leads to acquired PLX4032 resistance 
 
To investigate if chronic BRAF inhibition could lead to acquired drug 
resistance, four PLX4032-sensitive V600E melanoma cell lines (LM17, 
LM36, LM16, LM25) were chronically treated with the drug. The resistant 
variants (LM17R, LM36R, LM16R, LM25R) were obtained after 
treatment with PLX4032 (3.2 µM) for 96 hours, allowing the few surviving 
cells to regrow, and repeating treatment for 11 times (Figure 3). The 
LM17 and LM17R cell lines were used as a model system to investigate 
the molecular basis underlying acquired resistance to BRAF inhibitor. 
Whereas LM17 cells were highly sensitive to BRAF inhibition by 
PLX4032, LM17R cells showed reduced sensitivity to the antiproliferative 
effect of the drug and diminished cell cycle arrest, AK release and 
caspase 3 activation (Figure 4A). Western blot analysis showed that 
pERK, pAKT and cyclinD1 signaling was maintained after exposure to 
PLX4032 in LM17R in contrast with a strong signaling down regulation in 
LM17 cells (Figure 4B). Increase in pAKT level was noted in LM17R 
compared to LM17. These findings suggest that acquired resistance to 
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BRAFV600E inhibition could occur through reactivation of MAPK 
signaling and activation of alternative pathways as PI3K/ AKT. 
 
To investigate pathways activated in response to chronic treatment to 
PLX4032 a phospho-RTK array was used to assess phosphorylation of 
RTK in resistant compared to parental cells. pIGF1R levels resulted 
clearly upregulated among the tested RTK. Western blot analysis of 
pIGF1R confirmed the upregulation in the resistant line (Figure 4C). 
IGF1R can activate both the MAPK and PI3K signaling pathways, thus 
explaining the increase in pAKT levels observed in LM17R cells 
(Neudauer et al, 2003). Consistently with an increased dependency from 
AKT mediated signaling for proliferation, the effect of PI3K inhibitors, 
LY294002 and wortmannin, in LM17R versus LM17 was examined. Both 
LY294002 and wortmannin had antiproliferative effect as a single agent 
on both cell lines. In LM17R, the combination of LY294002 plus 
PLX4032  or wortmannin plus PLX4032 improved the response to either 
drug alone compared to the parental cell line (Figure 5A). These data 
suggest a link between BRAF inhibition and enhanced IGF1R-mediated 
PI3K signaling. The efficacy of the combined PI3K and MAPK pathway 
inhibitors was verified by western blot analysis for pAKT and pERK. 
Exposure of LM17R cells to LY294002 plus PLX4032 showed a clear 
reduction of pERK and a moderate  decrease of pAKT compared with 
either agent alone (Figure 5B). In contrast, in the intrinsically resistant 
LM20 cell line, the combination of LY294002 or wortmannin plus 
PLX4032 did not increase sensitivity to PLX4032 confirmed by minimal 
reduction in growth inhibition and unresponsiveness of pERK and pAKT 
(Figure 5C) indicating that additional signaling pathways may be 
involved in growth and survival of BRAFV600E cell lines showing 
primary resistance to PLX4032. 
 
4. Resistance to PLX4032 is independent from CRAF or MEK 
activity 
 
Several different mechanisms involved in resistance to BRAF inhibition 
have been described. Among them increased CRAF protein levels and 
switching from BRAF to CRAF dependency has been associated with 
the in vitro acquired resistance by BRAF inhibition to AZ628 (Montagut 
et al, 2008). To explore the role of CRAF expression in the persistent 
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MAPK signaling observed in the resistant lines, a RNA interference 
(RNAi) approach was used. LM38 and LM17R cells were transfected 
with CRAF or control siRNA for 24 hours before being treated for 24 
hours with PLX4032. Immunoblotting demonstrated specific and 
effective down-regulation of CRAF protein levels in both PLX4032-
resistant cell lines, LM38 and LM17R after transfection with CRAF 
specific siRNA. However, CRAF down-regulation did not affect pERK 
levels and sensitivity to PLX4032 indicating that CRAF is not involved in 
the activation of ERK in the resistant cell lines (Figure 6AB). To confirm 
that PLX4032-resistant lines remain dependent on MAPK activation for 
proliferation, the effect of MEK inhibition using the MEK inhibitor UO126 
was examined. Treatment with UO126 inhibited ERK phosphorylation 
and decreased proliferation in resistant cell lines indicating that other 
pathways may promote survival of these cells (Figure 6CD). 
 
5. Characterization of melanomas showing resistance to PLX4032 
 
Resistant cell lines showing a low sensitivity to PLX4032 may be less 
dependent on the BRAFV600E oncogenic signaling, relying on the co-
activation of other signaling pathways acting in parallel or upstream 
BRAF. In the search for new potential markers associated with the lack 
of sensitivity to PLX4032 and to identify candidate genes, Multiplex 
Ligation-dependent Probe Amplification (MLPA) analysis measuring the 
copy number of genes that are often deleted or amplified in tumors was 
used to genetically characterize the resistant melanomas. MLPA 
analysis showed no difference in the pattern of alterations between 
LM17 and LM17R, indicating that the acquisition of PLX4032 resistance 
is not associated to gain or loss of the tested genes (Part II, figure W2). 
In contrast amplification of CCND1 at 11q13 and of CTNNB1 at 3p21 
were detected in LM20 cells, while LM38 line showed a different pattern 
of alterations, which included MET amplification at 7q31. MET and 
CCND1 gene amplification in LM38 and in LM20 were confirmed by 
FISH analysis (Figure 7A) and gene copy number by qPCR (Part II, table 
W1). 
To further explore the mechanisms of drug resistance in an attempt to 
identify potential target molecules in BRAFV600E-mutated melanoma 
showing poor sensitivity to PLX4032, a proteomic-multiplexed analysis of 
the phosphotyrosine (pTyr) signaling and antibody validation was used 
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to screen pTyr  proteins modulated by treatment, comparing sensitive 
and resistant melanomas.  A significant degree of heterogeneity of 
profiles before and after PLX4032-treatment was observed (Part II, 
figure W3). MALDI-TOF mass spectrometry analysis was used to identify 
the most abundant phosphorylated proteins in untreated LM20 and 
LM38 cell lines. The identified proteins indicated that in LM20 cells pTyr-
based cell signaling was based on SRC/FAK axis, while MET axis was 
prevalently activated in LM38 cells (Figure 7C). These data appeared 
consistent with the genetic data showing MET gene amplification in 
LM38 cells and CTNNB1 in LM20 cells. In agreement with proteomic 
results, immunoblotting analysis revealed the phosphorylated MET 
(pMET) receptor in LM38 cells, and the phosphorylated form of STAT-3 
(pSTAT3), activated downstream SRC, in LM20 cells (Figure 7B). 
 
6. Combined targeting of MET and SRC signaling pathways to 
overcome PLX4032 resistance 
 
On the basis of the results of molecular profiling, MET and SRC 
represented new potential targets activated in LM38 and LM20 cell lines, 
intrinsically resistant to PLX4032. To see if targeting the MAPK signaling 
pathways at parallel nodes is effective in PLX4032- resistant cell lines 
the effect of combining PLX4032 with the MET inhibitor SU11274 or the 
SRC inhibitor BMS-354825 was tested. 
SU11274, when used alone, inhibited cell growth in most of melanoma 
cell lines including PLX4032-resistant cells. The combined treatment 
with SU11274 and PLX4032 resulted in a synergistic reduction of 
proliferation in the PLX4032-resistant cell line, LM38 (interaction index of 
2.5). Combination of SU11274 with PLX4032 enhanced G1 cell cycle 
arrest and AK release in the absence of caspase 3 activation (Figure 
8A). A similar antiproliferative effect was obtained after treating LM38 
cells with PLX4032 plus other MET inhibitors (JNJ, SGX523 and PHA) 
(Figure 8B). The combined blockade of both pathways was also verified 
by western blot analysis resulting in down-regulation of MET signaling 
through pFAK and pSHC while pERK and pAKT were not affected 
(Figure 8C). To determine whether MET and BRAF signaling pathways 
cooperate, LM38 cells were transfected with siRNA targeted to MET and 
MET silencing checked by testing MET expression by western blot 
analysis. The treatment with MET-siRNA plus PLX4032 showed a 
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significant inhibitory effect on cell proliferation compared to single agents 
alone, indicating an interaction between the two signaling pathways 
(Figure 8D). After  the treatment with MET-siRNA, cells displayed down-
regulation of pSHC levels but not of pERK and pAKT (Figure 8E). MET 
inhibition with drugs or by specific siRNA confirmed the role of MET 
signaling pathway in LM38 cells resistant to PLX4032. HGF/MET 
signaling promotes multiple biological activities, including motility and  
invasion. The effect of the combined treatment with PLX4032 and 
SU11274 on the ability of the cells to invade matrigel and migrate in vitro 
was evaluated. Indeed, blocking MET signaling by treatment with 
SU11274 alone or in combination with PLX4032 strongly inhibited 
matrigel invasion, confirming the role of MET signaling in mediating the 
invasive capacity in these cells (Figure 9A). Notably, a moderate effect 
was observed after treatment with PLX4032, indicating that BRAF 
inhibition, although not affecting cell growth, may alter the invasive 
activity of melanoma cells, even in the presence of exogenous HGF. 
Scratch wound assays showed that the combination of PLX4032 with 
SU11274 prevented wound closure, whereas the single drugs impaired 
wound healing to a limited extent, confirming the effect of the 
combination on cell migration (Figure 9C). In addition, the combined 
drugs downregulated the expression of β1-integrin, the receptor for the 
extracellular matrix protein laminin, involved in adhesive and invasive 
cellular processes (Figure 9B).  
BMS-354825 was reported to downregulate activated SRC, FAK, and 
EphA2 in melanoma cells and to inhibit proliferation in some melanoma 
cell lines (Eustace et al, 2008; Jilaveanu et al, 2011). Although BMS-
354825 by itself did not affect the viability of LM20 cells, the combined 
treatment  BMS-354825 plus PLX4032 significantly reduced growth in a 
synergistic manner (interaction index value of 2.1), increased AK release 
and the number of caspase 3-positive cells. A similar antiproliferative 
effect was obtained after treating LM20 cells with PLX4032 plus another 
SRC inhibitor, E804 (Figure 10A). BMS-354825 treatment  
downregulated pSRC levels and the downstream targets paxillin and 
p130CAS; in addition, BMS-354825 reduced pFAK levels. In contrast, no 
effect was detectable on pERK and pAKT levels, suggesting that it is not 
a necessary requirement to impair cell proliferation (Figure 10B). The 
combined treatment with PLX4032 and BMS-354825 decreased MMP-2 
production by LM20 melanoma cells, which was measured using gelatin-
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gel zymography (Figure 10C), and reduced the expression of β1-integrin 
(Figure 10D).  
SRC and MET have been implicated in the development and 
progression of several tumor types as a result of interaction with receptor 
tyrosine kinases and their downstream effectors leading to proliferation, 
cell growth, survival, motility, migration and angiogenesis (Stella et al, 
2010; Sen et al, 2011). Aberrant MET activation due to overexpression, 
mutations or gene amplifications, has been associated with poor clinical 
outcome and drug resistance in lung, hepatic, renal, and colorectal 
carcinoma (Stella et al, 2010). Genomic amplification of MET has been 
found in 47% of metastatic melanomas (Moore et al, 2008). It has been 
shown that targeted inhibition of MET either via SU11274 or specific 
small interfering RNA (siRNA) led to decreased cell growth and viability 
of melanoma cells. SU11274 inhibition of MET abrogated tyrosine 
phosphorylation of cellular proteins, including MET itself, as well as its 
downstream signaling proteins (Puri et al, 2007; Kenessey et al, 2010). 
These findings implicate the MET pathway in melanoma progression and 
suggest that MET inhibition might provide an effective therapeutic 
approach. The nonreceptor protein tyrosine kinase SRC plays a crucial 
role in the signal transduction pathways involved in cell division, motility, 
adhesion, and survival in both normal and cancer cells. Aberrant 
expression and activation of SRC occur in breast, prostate, lung, and 
colorectal carcinomas, in association with poor clinical outcome (Sen et 
al, 2011). Simultaneous inhibition of BRAF and MET/SRC signaling 
pathways showed antiproliferative and proapoptotic effects in PLX4032-
resistant cells. In addition, these results demonstrated that the 
combination of SU11274 or BMS-354825 plus PLX4032 reduced 
invasive and migratory capacities of PLX4032-resistant cell lines, 
suggesting that they may represent effective drug combinations to inhibit 
melanoma growth and dissemination. 
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Conclusions and Future Prospects 
 
The results collected in this thesis confirmed the high in vitro specificity 
of the BRAF inhibitor, PLX4032 for a subset of melanoma cell lines 
bearing mutant BRAFV600E. The antiproliferative effect of PLX4032 was 
accompanied by cell cycle arrest, increase in cell death and inhibition of 
ERK phosphorylation, indicating that PLX4032 blocks the downstream 
signaling resulting from constitutively active BRAFV600E. A large panel 
of melanoma cell lines showed differences in the sensitivity to PLX4032, 
and two BRAFV600E melanoma cell lines showing intrinsic resistance to 
the cytotoxic effects of the drug were identified. Data reported here 
showed that differential response to PLX4032 in BRAFV600E mutant 
melanoma cell lines may be explained by different resistance 
mechanisms. Sensitive cell lines may have a preferential MAPK 
pathway-addiction, and cells with low sensitivity may be less dependent 
on the BRAFV600E oncogenic signaling, relying on the co-activation of 
other signaling pathways. The genetic and molecular characterization of 
the PLX4032-resistant lines showed constitutive activation of MET and 
SRC kinases, representing potential new candidate targets involved in 
primary resistance. Inhibition of MET and SRC signaling by specific 
inhibitors in combination with PLX4032 restrain growth, survival and 
invasive capacity of melanoma cells bypassing resistance to BRAF 
inhibition. Taken together, the results reported here highlight the 
complexity and functional redundancy within the melanoma signaling 
network and support evidence that combinatorial approaches targeting 
MAPK pathway at different nodes and/or parallel signal transduction 
pathways may represent a strategy to override resistance to BRAF 
inhibitors.  
 
An issue that deserves consideration in the context of BRAF targeting 
drugs is the immune response at tumor site. Significant clinical results 
have been obtained with Ipilimumab, a human monoclonal antibody that 
blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA4) improving 
survival in patients with metastatic melanoma (Hodi et al, 2010). 
Oncogenic BRAF signaling has been shown to contribute to melanoma 
immune escape by inducing the expression of immunosuppressive 
cytokines such as IL8, IL6, IL10, TGFβ and VEGF (Zou et al, 2005). 
Cytokine genes including IL8 were identified as transcriptional targets of 
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BRAF signaling by gene expression profiling (Packer et al, 2009). Thus, 
BRAF represents a potential molecular target not only for inhibiting 
cellular proliferation but also for melanoma induced suppression of 
immune surveillance. It has been reported that MEK inhibitor UO126 or 
RNAi for BRAFV600E decreased production of IL10, VEGF and IL6 from 
melanoma cells (Sumimoto et al, 2006). In vivo, BRAF inhibitors were 
showed to induce marked T cell infiltration into metastatic melanoma 
lesions (Wilmott et al, 2012). These findings corroborate the results of in 
vitro studies performed on mutant BRAF melanoma cell lines suggesting 
that inhibition of the MAPK pathway with a BRAFV600E inhibitor resulted 
in increased expression of melanocyte differentiation antigens, and 
improved tumor cells recognition by antigen-specific T-cell (Kono et al, 
2006; Boni et al, 2010). T-cell viability and function was not 
compromised when tested in vitro after treatment with BRAFV600E 
inihibitor at therapeutic concentrations (Comin-Anduix et al, 2010). 
These data indicate that BRAF inhibitors render melanoma cells more 
susceptible to immune attack, and combination therapies including 
BRAF inhibitors and immunotherapy may be developed to extend the 
duration of treatment response. I have recently begun to study the 
effects of BRAF and MEK inhibitors on the modulation of melanoma 
differentiation antigens and production of cytokines in a panel of 
melanoma cell lines with intrinsic or acquired resistance to PLX4032. 
The cell lines are going characterization for GF and cytokines network 
profiles associated to resistance to BRAF inhibition in order to identify 
cytokines signaling representing potential new targets for combined 
treatment. 
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Figures 
 
 
 
Figure 1. Effects of PLX4032 on BRAFV600E-mutated melanoma cells expressing or 
lacking PTEN. (A) Inhibitory effect of PLX4032 on cell growth in a panel of 27 genetically 
characterized melanoma cell lines after 72 hours of drug exposure. The different 
mutation profiles are indicated. Ampl, amplification; neg, negative. (B) Inhibition of cell 
growth (72 hours), AK release (72 hours), activated caspase 3 (48 hours), percentages 
of cells in sub G1, G1, S and G2/M phases of cell cycle (24 hours) after treatment with 
PLX4032 (3.2 µM). The percentage of growth was calculated by MTT assays as: (OD570 
of wells that contained the drug/OD570 of the drug-free wells) × 100. Error bars, SD.  
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Figure 2. Modulation of phospho-signaling pathways after 24 hours PLX4032 treatment 
(3.2 µM). 
 
 
 
 
 
 
 
 
 
 
Figure 3. PLX4032-resistant variants selected by longterm exposure. Calculated IC50 
values were 0.2 and 4 µM for LM17 and LM17R, 0.07 and 7.1 µM for LM36 and LM36R, 
0.09 and 8.5 µM for LM16 and LM16R, 0.1 and >10 µM for LM25 and LM25R. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. LM17R variants showed decreased sensitivity to inhibition of cell growth, 
induction of cell death and cell cycle arrest after PLX4032 treatment. (A) Cell growth, cell 
death, caspase 3 staining, and cell cycle analysis were tested at 72, 48, and 24 hours of 
treatment with PLX4032 (3.2 µM). ∗: p < 0.0001 by Student’s t test. (B-C) Enhanced 
ERK, AKT and IGF1R signaling in the resistant variant LM17R. Expression levels as 
evaluated by western blot analysis in parental and resistant cells treated or not with 
PLX4032 (3.2 µM for 24 hours).  
 
 Elisabetta Vergani 
 
35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Cotreatment with PI3K inhibitors and PLX4032 inhibits growth and signaling in 
LM17R melanoma. (A) Growth inhibition (72 hours), in LM17, LM17R and LM20 cells 
treated with PLX4032 and/or LY294002 (60 µM)/wortmannin (10 µM). ∗: p < 0.0001 by 
one-way ANOVA followed by the Bonferroni correction. (B-C) Western blot analysis 
showing the regulation of downstream PI3K targets in LM17R compared to LM17 cells 
and in the resistant line LM20 after 24 hours of treatment with PLX4032 and/or 
LY294002/wortmannin.  
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Figure 6. Resistance to PLX4032 is independent of CRAF and MEK. (A) Western blot 
analysis of LM38 and LM17R cells that were transfected with CRAF or control siRNA for 
24 hours before being treated for 24 hours with PLX4032 (3.2 µM), showing CRAF 
protein levels downregulated to 14% and to 20%, respectively, as determined by 
quantification of the signal by Image Quant v5.2 software. (B) LM38 and LM17R cells 
were treated for 24 hours with CRAF or control siRNA before 72 hours of treatment with 
PLX4032 (3.2 µM). Absorbance at 570 nm after MTT staining is shown, indicating that 
CRAF inhibition does not increase sensitivity to PLX4032. (C) The proliferation of 
melanoma LM20, LM38, LM17R, and LM17 cells was similarly inhibited by 72 hours of 
treatment with UO126. (D) Levels of pERK are downregulated after 24 hours of 
incubation with UO126 (25 µM).  
 
 
 
 
 
 
 
 
 Elisabetta Vergani 
 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Molecular characteristics of the PLX4032-resistant LM20 and LM38 cell lines. 
(A) FISH analysis with orange labeled probe targeting MET gene and green control 
probe in LM38 cells. Four green and more than eight orange signals are shown in cells 
indicated by the arrows. (B) Detection of pMET, pSRC, and pSTAT3 signals after 24 
hours of treatment with PLX4032 (3.2 µM) in LM38 and LM20 cells by Western blot 
analysis. (C) Identification of some relevant immunoaffinity-purified proteins from LM38 
and LM20 cell lines. Top: Coomassie blue staining of anti-pTyr affinity-purified proteins 
from LM38 cells. Bottom: Silver staining of anti-pTyr affinity-purified proteins from LM20 
cells. Protein extracts were incubated with antipTyr agarose-conjugated antibody. Bound 
proteins were washed, eluted, and resolved by 4% to 12% SDS-PAGE. Mw indicates 
molecular weight markers. Swiss Prot ID indicates accession number. 
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Figure 8. Cotreatment with MET inhibitor and PLX4032 inhibits growth and increased 
cell death in LM38-resistant melanoma. (A) Growth inhibition (72 hours), AK release (72 
hours), and cell cycle (24 hours) in LM38 cells treated with PLX4032 and/or SU11274. 
∗:p < 0.0001 by one-way ANOVA followed by the Bonferroni correction. : interaction 
index = 2.5. Interaction index values was used to evaluate drug interaction with values 
greater than 1 indicating synergism. (B) The inhibitory effect of PLX4032 combined with 
JNJ-38877605 (J), PHA-665752 (PHA), and SGX-523 (SGX) on proliferation is shown. 
: interaction index = 2.2, 1.22, and 1.33, respectively. ∗: p < 0.0001 by one-way 
ANOVA followed by the Bonferroni correction. (C) Western blot analysis showing the 
regulation of downstream MET targets in LM38 cells after 24 hours of treatment with 
PLX4032 and/or SU11274. (D) LM38 cells were treated for 96 hours with MET or control 
siRNA and with PLX4032 (3.2 µM). After MTT staining, the percentage of cell growth was 
calculated compared with the untreated control. ∗: p < 0.0001 by one-way ANOVA 
followed by the Bonferroni correction. (E) Western blot analyses of LM38 cells showing 
modulation of MET signaling after 96 hours of the indicated treatments. MET protein 
levels were downregulated to 20%, as determined by quantification of the signal by 
Image Quant v5.2 software. 
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Figure 9. Cotreatment with MET inhibitor and PLX4032 inhibits invasion, and migration 
of LM38-resistant melanoma. (A) The Matrigel cell invasion assay showing the effect of 
exposure to PLX4032, SU11274 or both in LM38 cells. The percent inhibition of 
migration at 24 hours with or without HGF compared with that of untreated cells is 
shown. ∗: p < 0.0001 compared with treatment with PLX4032 by Student’s t test. (B) 
FACS analysis of β1-integrin expression after 24 hours of exposure to PLX4032 and/or 
SU11274 in LM38 cells. Mean fluorescence intensity after treatment is indicated. (C) 
Scratch wound assay showing closure of a scratch wound in cultured LM38 cells under 
control conditions or in the presence of PLX4032, SU11274, or both for 72 hours. 
Medium was replaced every day to remove detached dead cells. Magnification, x2.5. − 
indicates untreated control; P, PLX4032 (3.2 µM); S, SU11274 (10 µM). 
BRAF as a target for malignant melanoma  
 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Cotreatment with SRC inhibitors and PLX4032 inhibits LM20 melanoma cell 
growth and downregulates MMP-2 and β1-integrin. (A) Growth inhibition, AK release (72 
hours), and activated caspase 3 (48 hours) in LM20 cells that were treated with PLX4032 
and/or BMS-354825. ∗: p < 0.0001 by one-way ANOVA followed by the Bonferroni 
correction. : interaction index = 2.1. Interaction index values was used to evaluate drug 
interaction with values greater than 1 indicating synergism. Bottom right, growth 
inhibitory effect of PLX4032 combined with the SRC inhibitor E804. ∗: p < 0.0001 
compared with single treatments by Student’s t test. (B) Western blot analysis showing 
regulation of downstream SRC targets in LM20 cells after 24 hours of treatment with 
PLX4032 and/or BMS-354825. (C) Gelatin zymography detecting MMP-2 in supernatants 
from LM20 cells collected after 24 hours of exposure to PLX4032, BMS-354825, or their 
combination. MMP-2 band was detectable at 72 kDa. (D) FACS analysis of β1-integrin 
expression after 24 hours of exposure to PLX4032 and/or BMS-354825 in LM20 cells. 
Mean fluorescence intensity after treatment is indicated. − indicates untreated control; B, 
BMS-354825 (100 nM); E, E804; P, PLX4032 (3.2 µM); pos, positive control. 
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